Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Sino Biopharmaceutical Limited
  6. News
  7. Summary
    1177   KYG8167W1380

SINO BIOPHARMACEUTICAL LIMITED

(1177)
  Report
Delayed Hong Kong Stock Exchange  -  03:08 2022-11-25 am EST
4.240 HKD   -1.17%
11/21Sector Update: Health Care Stocks Advance Modestly
MT
11/02Sino Biopharmaceutical's Q3 Revenue Rises 21%; Shares Rise 5%
MT
11/01Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chia Tai-Tianqing Signs Agreement for Lanifibranor

09/22/2022 | 08:19am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
INVENTIVA 0.50% 4.055 Real-time Quote.-65.46%
MSCI TAIWAN (STRD) 0.49% 533.483 Real-time Quote.-28.47%
SINO BIOPHARMACEUTICAL LIMITED -1.17% 4.24 Delayed Quote.-22.34%
All news about SINO BIOPHARMACEUTICAL LIMITED
11/21Sector Update: Health Care Stocks Advance Modestly
MT
11/02Sino Biopharmaceutical's Q3 Revenue Rises 21%; Shares Rise 5%
MT
11/01Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023
CI
11/01Sino Biopharmaceutical Limited Reports Unaudited Revenue Results for the Third Quarter ..
CI
11/01Sino Biopharmaceutical Limited Announces Resignation of Wang Shanchun as Executive Dire..
CI
09/29Trustee Purchases Sino Biopharmaceutical Shares for $1.3 Million
MT
09/28Trustee Purchases 2,780,000 Sino Biopharmaceutical Shares for $1.3 Million
MT
09/26Chinese Regulator Approves Clinical Trial of Sino Biopharmaceutical's COVID-19 Medicine..
MT
09/22Inventiva ADRs Rise 22% After Licensing Deal With Chia Tai-Tianqing Pharma
DJ
09/22Chia Tai-Tianqing Signs Agreement for Lanifibranor
MT
More news
Analyst Recommendations on SINO BIOPHARMACEUTICAL LIMITED
More recommendations
Financials
Sales 2022 30 028 M 4 188 M 4 188 M
Net income 2022 3 992 M 557 M 557 M
Net cash 2022 7 274 M 1 014 M 1 014 M
P/E ratio 2022 18,4x
Yield 2022 1,41%
Capitalization 71 885 M 10 025 M 10 025 M
EV / Sales 2022 2,15x
EV / Sales 2023 1,83x
Nbr of Employees 25 552
Free-Float 52,1%
Chart SINO BIOPHARMACEUTICAL LIMITED
Duration : Period :
Sino Biopharmaceutical Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINO BIOPHARMACEUTICAL LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 3,89 CNY
Average target price 6,52 CNY
Spread / Average Target 67,7%
EPS Revisions
Managers and Directors
S Y Tse Chief Executive Officer & Executive Director
Jia yin Ma Group Chief Financial Officer
Theresa Tse Chairman
Zheng Fei Lu Independent Non-Executive Director
Da Kui Li Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SINO BIOPHARMACEUTICAL LIMITED-22.34%10 025
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY30.95%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555